Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 300 Carcinoma, Non-Small-Cell Lung 80 Squamous Cell Carcinoma of Head and Neck 59 Carcinoma, Renal Cell 58 Neoplasms 40 Neoplasm Metastasis 36 Colorectal Neoplasms 36 Stomach Neoplasms 29 Carcinoma, Merkel Cell 29 Triple Negative Breast Neoplasms 28 Ovarian Neoplasms 28 Carcinoma, Transitional Cell 27 Uterine Cervical Neoplasms 24 Skin Neoplasms 24 Head and Neck Neoplasms 24 Lung Neoplasms 22 Breast Neoplasms 21 Carcinoma, Hepatocellular 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Esophageal Neoplasms 18 Pancreatic Neoplasms 16 Uveal Melanoma 14 Small Cell Lung Carcinoma 14 Sarcoma 14 Urinary Bladder Neoplasms 12 Lymphoma 11 Kidney Neoplasms 11 Endometrial Neoplasms 11 Brain Neoplasms 11 Prostatic Neoplasms 10

Interventions

pembrolizumab 1 Temozolomide 1 Paclitaxel 1 Dacarbazine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Melanoma × pembrolizumab × Dermatologic × Clear all

NCT03407170 2020-07-15

KEYNOTE-161

Merck Sharp & Dohme LLC

Phase 2 Terminated

1 enrolled 3 charts

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡